Welcome to our dedicated page for Idexx Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on Idexx Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a broad range of diagnostic and information technology-based products and services to practicing veterinarians across the globe. Headquartered in Southern Maine, the company operates through more than 70 locations worldwide, serving customers in over 175 countries and employing more than 11,000 people.
IDEXX’s primary business focuses on pet health, offering products such as in-clinic diagnostic tests, instrumentation, reference laboratory and telemedicine consultation services, and practice management software. These products enhance veterinarians' ability to provide advanced medical care, improve staff efficiency, and build more economically successful practices. The company is also involved in developing diagnostic tests for the global production animal industry, including poultry and livestock, and tests for the quality and safety of water.
An important recent achievement for IDEXX is the launch of the SNAP® Leish 4Dx® Test, designed to diagnose vector-borne diseases like canine leishmaniosis in regions where these diseases are endemic. This new test will be available in Europe and Asia starting February 2024. Another significant accomplishment is the expansion of the Fecal Dx® antigen testing platform, which includes the addition of Cystoisospora, a common intestinal parasite. This expansion will roll out in North America in March 2024 and globally by the third quarter of 2024.
IDEXX also launched Vello, a software solution aimed at improving communication between veterinary practices and pet owners. This tool supports better health outcomes by engaging pet owners through digital means and is integrated with IDEXX's existing practice management software like ezyVet®, Neo®, and Cornerstone®.
Financially, IDEXX is robust, with a diverse revenue stream sourced from various products and services, including diagnostic equipment, tests, and software solutions. Approximately 35% of its revenue comes from international markets. The company is a member of the S&P 500® Index, highlighting its significant role in the industry.
For more information about IDEXX’s products and services, visit idexx.com.
IDEXX Laboratories, a leader in veterinary diagnostics, will announce its third quarter financial results for 2021 on November 2, 2021, before markets open. The company will host an analyst conference call at 8:30 a.m. ET on the same day. Access to the live call will be available through IDEXX's website and via telephone. IDEXX employs around 9,800 people and provides diagnostics and software for veterinary, livestock, and water quality sectors, serving customers in over 175 countries.
IDEXX Laboratories (NASDAQ: IDXX) will host a virtual Investor Day on August 12, 2021, from 10:00 AM to 12:30 PM EDT. This event features presentations by senior leadership, including CEO Jay Mazelsky and CFO Brian McKeon, followed by a Q&A session. Participants can access the live webcast and slide presentations via IDEXX's investor page. An archived replay will be available shortly after the event. IDEXX is recognized for its innovative solutions in veterinary diagnostics, software, and water testing.
IDEXX Laboratories announced strong second quarter results for 2021, with a reported revenue growth of 30% and organic revenue growth of 25%. The Companion Animal Group (CAG) Diagnostics saw recurring revenue growth of 30% reported and 26% organic. The earnings per share (EPS) reached $2.34, a 36% increase. The company raised its 2021 revenue guidance to $3.170 - $3.205 billion and EPS outlook to $8.20 - $8.36. Growth drivers include strong demand for CAG Diagnostics and expansion in water testing revenues.
IDEXX Laboratories, a leading veterinary diagnostics company, will release its 2021 second quarter financial results on July 30, 2021, before market opening. The accompanying analyst conference call is scheduled for 8:30 a.m. ET on the same day. Interested parties can access a live webcast at www.idexx.com/investors or join via telephone by dialing 1-888-771-4371 or 1-847-585-4405 with access code 50183464. An archived version of the call will be available after 1:00 p.m. ET and remain accessible for one year.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has acquired ezyVet®, a leading cloud-based practice information management system. This strategic acquisition enhances IDEXX's portfolio, allowing the company to offer comprehensive cloud software solutions that improve veterinary practice efficiency and care standards. The acquisition includes Vet Radar, an innovative electronic treatment sheet solution. IDEXX aims to leverage ezyVet's technology to enhance customer satisfaction and support veterinarians in their business growth.
IDEXX Laboratories (NASDAQ: IDXX) will participate in the Stifel Virtual Jaws & Paws Conference on June 2, 2021, at 10:00 am (EDT). CEO Jay Mazelsky and CFO Brian McKeon will engage in a virtual fireside chat. Investors can access the live audio webcast on the IDEXX website, with an archived version available later. Additionally, IDEXX will host its 2021 Virtual Investor Day on August 12, 2021, starting at 10:00 am (EDT). Further details will be announced closer to the date.
IDEXX Laboratories reported strong first quarter results for 2021, with revenues of $778 million, marking a 24% increase and 21% organic growth. Companion Animal Group (CAG) Diagnostics drove this growth, showing a 27% increase in recurring revenue. EPS rose to $2.35, an 82% growth. The company raised its 2021 revenue guidance to between $3,105 million and $3,160 million. Additionally, IDEXX's operating margins improved significantly, reflecting robust demand for its diagnostics products. However, water revenue saw a modest decline of 3% organically.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the release date for its first quarter financial results, which is set for May 4, 2021, prior to market opening. An analyst conference call will occur at 8:30 a.m. ET on the same day. Interested parties may access the call via a live webcast on the IDEXX investor website. A recorded version will be available after 1:00 p.m. ET and will remain accessible for one year. IDEXX is a leading provider of veterinary diagnostics and software, employing over 9,000 individuals globally.
IDEXX Laboratories, a leader in veterinary diagnostics, will participate in two significant virtual conferences. On February 25 at 11:45 am EST, CEO Jay Mazelsky and CFO Brian McKeon will join a fireside chat at the BofA Securities Animal Health Summit. The following week, on March 1 at 9:10 am EST, Jay Mazelsky will speak at the 42nd Annual Raymond James Institutional Investors Conference. Investors can access live presentations and archives on the IDEXX website.
IDEXX Laboratories reported strong fourth quarter results with 19% revenue growth, driven by a 23% increase in CAG Diagnostics recurring revenue. The company's full-year EPS rose to $6.71, a 37% increase on a reported basis. For 2021, IDEXX forecasts revenue of $3,065M - $3,120M and EPS between $7.39 and $7.71, indicating growth of 10% - 14%. The 2020 performance was supported by operating margin improvements and strong market demand in companion animal healthcare. However, growth was moderated by COVID-19 impacts on new instrument placements.
FAQ
What is the current stock price of Idexx Laboratories (IDXX)?
What is the market cap of Idexx Laboratories (IDXX)?
What is IDEXX Laboratories, Inc.?
Where is IDEXX Laboratories headquartered?
What are some key products and services offered by IDEXX?
What recent products has IDEXX Laboratories launched?
How many countries does IDEXX Laboratories serve?
How many people does IDEXX Laboratories employ?
What is the new software solution IDEXX launched?
What percentage of IDEXX's revenue comes from international markets?
Is IDEXX part of any major stock index?
Where can I find more information about IDEXX's products and services?
